Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1532-5415.2009.02712.xDOI Listing

Publication Analysis

Top Keywords

galantamine aggravated
4
aggravated orthostatic
4
orthostatic hypotension
4
hypotension people
4
people alzheimer's
4
alzheimer's disease
4
galantamine
1
orthostatic
1
hypotension
1
people
1

Similar Publications

Dextran Sodium Sulphate-Induced Gastrointestinal Injury Further Aggravates the Impact of Galantamine on the Gastric Myoelectric Activity in Experimental Pigs.

Pharmaceuticals (Basel)

June 2021

Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, 500 01 Hradec Kralove, Czech Republic.

Galantamine has been used as a treatment for Alzheimer disease. It has a unique, dual mode of action (inhibitor of acetylcholinesterase and allosteric modulator of nicotinic acetylcholine receptors). Nausea (in about 20%), vomiting (10%) and diarrhoea (5-7%) are the most common side effects.

View Article and Find Full Text PDF

General anesthesia with Nembutal (40 mg/kg) dramatically decreased the power of all waves of HRV spectrum in rats, especially in LF and VLF frequency bands, but the HR and respiration rate were little changed. At this, individual spectral peaks in HF range were observed at the same frequencies (1.3-1.

View Article and Find Full Text PDF

[Not Available].

Therapie

July 2016

Pôle de Recherche et d'Épidémiologie Clinique, Centre Hospitalo-Universitaire de Caen, Caen, France.

Purpose: The modalities for anti-dementia drugs' discontinuation are not consensual.

Objective: The objectives of the study were the followings, describe: i) the reasons for discontinuation of anti-dementia drugs of patients treated in a residency for dependent elderly people, ii) security of sudden discontinuation, iii) evolution of troubles.

Methods: Our longitudinal descriptive pilot study aimed at observing consequences of the sudden discontinuation of anti-dementia drugs in a population with a moderate to severe stage of Alzheimer's disease.

View Article and Find Full Text PDF

Translational Challenge Models in Support of Efficacy Studies: Effect of Cerebral Hypoxia on Cognitive Performances in Rodents.

CNS Neurol Disord Drug Targets

October 2017

Département de Pharmacologie Médicale-Centre Hospitalier Universitaire, Université Lille-Nord-de-France, Faculté de Médecine, 1, Place de Verdun, 59-045, Lille Cedex, France.

Empirical evidence currently supports the idea that neurovascular dysfunction is involved in the neurodegenerative process of Alzheimer's disease (AD). In fact, epidemiological studies report that i) vascular risk factors are directly associated with an increased incidence of AD and ii) vascular lesions are frequently co-existent with AD. The neurovascular unit is a key control system for oxygen and nutrients exchange between neurons and microvessels so the integrity of this system is essential for neuronal activity and cell survival.

View Article and Find Full Text PDF

Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.

Curr Neuropharmacol

December 2016

Brain & Mind Centre, University of Sydney, 94 Mallett Street, Camperdown, New South Wales, Australia.

Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most common neurodegenerative disorders encountered in clinical practice. Whilst dementia has long been synonymous with AD, it is becoming more widely accepted as part of the clinical spectrum in PD (PDD). Neuropsychiatric complications, including psychosis, mood and anxiety disorders, and sleep disorders also frequently co-exist with cognitive dysfunctions in AD and PDD patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!